News
PRQR
1.960
-2.49%
-0.050
ProQR Therapeutics Announces Board Nomination and AGM
TipRanks · 2d ago
BRIEF-ProQR Therapeutics NV Intends To Change Board Structure From Two-Tier Structure To One-Tier Board
Reuters · 2d ago
PROQR NOMINATES MARTIN MAIER, PHD TO BOARD AND ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS TO BE HELD MAY 22, 2024
Reuters · 2d ago
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
ProQR Therapeutics will present new preclinical data for its Axiomer™ RNA editing technology platform at the American Society of Gene & Cell Therapy Annual Meeting, May 7-11, 2024. ProQR is a company dedicated to changing lives through transformative RNA therapies.
Barchart · 3d ago
Weekly Report: what happened at PRQR last week (0415-0419)?
Weekly Report · 3d ago
ProQR Solidifies Lead in RNA Therapy Innovation
TipRanks · 6d ago
ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio
ProQR has successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer. The opposition was filed in June 2021 with the European Patent Office. ProQR invented the use of endogenous ADAR in RNA editing in 2014.
Benzinga · 6d ago
PROQR ACHIEVES SUCCESSFUL DEFENSE OF NEW CHALLENGE TO ITS AXIOMER™ IP PORTFOLIO
Reuters · 6d ago
ProQR Therapeutics Price Target Raised to $2.00/Share From $1.80 by Citigroup
Dow Jones · 04/18 16:16
ProQR Therapeutics Is Maintained at Neutral by Citigroup
Dow Jones · 04/18 16:16
Weekly Report: what happened at PRQR last week (0408-0412)?
Weekly Report · 04/15 12:01
Weekly Report: what happened at PRQR last week (0401-0405)?
Weekly Report · 04/08 12:08
Weekly Report: what happened at PRQR last week (0325-0329)?
Weekly Report · 04/01 12:04
Weekly Report: what happened at PRQR last week (0318-0322)?
Weekly Report · 03/25 12:08
Weekly Report: what happened at PRQR last week (0311-0315)?
Weekly Report · 03/18 12:06
3 Best Stocks to Buy Now, 3/15/2024, According to Top Analysts 
TipRanks · 03/15 06:00
ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 11:27
ProQR Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 03/14 10:38
ProQR Therapeutics Price Target Raised to $2.50/Share From $2.00 by Chardan Capital
Dow Jones · 03/14 10:38
Buy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic Disorders
TipRanks · 03/14 10:27
More
Webull provides a variety of real-time PRQR stock news. You can receive the latest news about Proqr Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About PRQR
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).